New data from the Daybreak trial shows that Zeposia (ozanimod), a treatment for relapsing forms of multiple sclerosis, effectively reduced brain volume loss in patients for up to five years. The study also demonstrated a declining incidence of treatment-related adverse events over an extended period, suggesting a favorable safety profile for the drug.